Atai CEO Rao optimistic about psychedelic therapies despite Lykos setback
The U.S. FDA rejection of an MDMA-based drug from Lykos Therapeutics for PTSD in August 2024 has not dimmed hopes that other psychedelic-oriented therapies can gain approval, according to the CEO of ...